# Illumina raises outlook as clinical sequencing demand supports installations

_Published Friday, October 30, 2026 at 3:19 PM EDT · Capital · Latest · Tier 2 — Notable_

![Illumina raises outlook as clinical sequencing demand supports installations — Primary](https://s.yimg.com/lo/mysterio/api/f5709f3b24d69916cbf4a017b659a98a244601bece9eed9d0b1a7fe151457274/lightyear_networkapi/resizefill_w1200%3Bquality_80%3Bformat_webp/https%3A%2F%2Fmedia.zenfs.com%2Fen%2Fzacks.com%2Fb42cf29dcf4c07c4004a767ee1448de3.png)

Illumina raised its 2026 revenue guidance to $4.64-$4.66 billion from $4.60-$4.64 billion following third-quarter clinical sequencing demand and NovaSeq X installations, Yahoo Finance reported. Adjusted earnings guidance increased to $5.40-$5.45 per share from $5.30-$5.40.

Management reported more than 80 NovaSeq X placements during the quarter. The platform now accounts for 84% of high-throughput sequencing volume and 60% of associated revenue. Sequencing consumables revenue increased 6% to $792 million, while research and applied consumables declined 6%. Management continued to expect research-market declines during 2026.

## Sources

- [Yahoo Finance](https://finance.yahoo.com/healthcare/articles/ilmn-q3-earnings-call-highlights-130000209.html)

---
Canonical: https://techandbusiness.org/newswire/nvH_j4gX7l_Xn2ZE-oSz2H
Published: 2026-10-30T19:19:42.086Z
Story chronology: 2026-10-30T13:00:00.000Z
Retrieved: 2026-10-30T22:10:28.081Z
Publisher: Tech & Business (techandbusiness.org)